Which has stronger valuation & earnings, ADIL or NRSN?

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is ADIL or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% NeuroSense Therapeutics N/A N/A N/A

Which has better earnings and valuation, ADIL or SKYE?

Skye Bioscience is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A Skye Bioscience N/A N/A -$55.92M -$1.44 N/A

Is ADIL or SKYE more profitable?

Adial Pharmaceuticals' return on equity of -162.82% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% Skye Bioscience N/A -217.27% -162.39%

Do analysts rate ADIL or ALVR?

Adial Pharmaceuticals currently has a consensus target price of $17.17, suggesting a potential upside of 517.51%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Adial Pharmaceuticals is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, ADIL or ALVR?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is ADIL or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% AlloVir N/A -71.03% -61.27%

Which has higher earnings & valuation, JSPR or ADIL?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is JSPR or ADIL more profitable?

Adial Pharmaceuticals' return on equity of -162.82% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% Adial Pharmaceuticals N/A -162.82% -127.58%

Which has stronger earnings & valuation, ADIL or MRKR?

Marker Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A Marker Therapeutics N/A N/A -$12.16M -$0.61 N/A

Adial Pharmaceuticals (ADIL) Competitors

$2.78 +0.10 (+3.73%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$2.65 -0.13 (-4.68%)

As of 07/24/2026 07:34 PM Eastern

Compare

ADIL vs. NRSN, SKYE, ALVR, JSPR, and MRKR

Should you buy Adial Pharmaceuticals stock or one of its competitors? MarketBeat compares Adial Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adial Pharmaceuticals include NeuroSense Therapeutics (NRSN), Skye Bioscience (SKYE), AlloVir (ALVR), Jasper Therapeutics (JSPR), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.

How does Adial Pharmaceuticals compare to NeuroSense Therapeutics?

Adial Pharmaceuticals (NASDAQ:ADIL) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.89 beat NeuroSense Therapeutics' score of 0.94 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
NeuroSense Therapeutics	Positive

NeuroSense Therapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
NeuroSense Therapeutics	N/A	N/A	N/A

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Adial Pharmaceuticals currently has a consensus target price of $17.17, suggesting a potential upside of 517.51%. NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 1,311.73%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adial Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Summary

NeuroSense Therapeutics beats Adial Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Skye Bioscience?

Adial Pharmaceuticals (NASDAQ:ADIL) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Skye Bioscience is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Adial Pharmaceuticals and Adial Pharmaceuticals both had 1 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.89 beat Skye Bioscience's score of 1.87 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
Skye Bioscience	Very Positive

Adial Pharmaceuticals presently has a consensus price target of $17.17, suggesting a potential upside of 517.51%. Skye Bioscience has a consensus price target of $8.50, suggesting a potential upside of 1,203.88%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Adial Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.94, indicating that its stock price is 194% more volatile than the broader market.

Adial Pharmaceuticals' return on equity of -162.82% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Skye Bioscience	N/A	-217.27%	-162.39%

Summary

Skye Bioscience beats Adial Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to AlloVir?

Adial Pharmaceuticals (NASDAQ:ADIL) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Adial Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

AlloVir's return on equity of -71.03% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
AlloVir	N/A	-71.03%	-61.27%

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Adial Pharmaceuticals currently has a consensus target price of $17.17, suggesting a potential upside of 517.51%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Adial Pharmaceuticals is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for AlloVir. Adial Pharmaceuticals' average media sentiment score of 1.89 beat AlloVir's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
AlloVir	Neutral

Summary

Adial Pharmaceuticals beats AlloVir on 8 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Jasper Therapeutics has a beta of 3.07, suggesting that its share price is 207% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

79.8% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.89 beat Jasper Therapeutics' score of 0.63 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Positive
Adial Pharmaceuticals	Very Positive

Adial Pharmaceuticals' return on equity of -162.82% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Jasper Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 1,643.17%. Adial Pharmaceuticals has a consensus price target of $17.17, indicating a potential upside of 517.51%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Jasper Therapeutics beats Adial Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Marker Therapeutics?

Adial Pharmaceuticals (NASDAQ:ADIL) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Adial Pharmaceuticals currently has a consensus target price of $17.17, indicating a potential upside of 517.51%. Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 719.67%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Marker Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.61	N/A

In the previous week, Adial Pharmaceuticals and Adial Pharmaceuticals both had 1 articles in the media. Adial Pharmaceuticals' average media sentiment score of 1.89 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
Adial Pharmaceuticals	Very Positive
Marker Therapeutics	Very Positive

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Adial Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Adial Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Summary

Marker Therapeutics beats Adial Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export

Metric	Adial Pharmaceuticals	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.75M	$434.82M	$6.86B	$12.25B
Dividend Yield	N/A	3.90%	2.67%	9.79%
P/E Ratio	-0.35	3.16	27.14	23.64
Price / Sales	N/A	6,592.20	517.01	89.03
Price / Cash	N/A	13.13	50.54	59.64
Price / Book	0.59	83.70	10.28	6.07
Net Income	-$7.98M	-$96.07M	$3.60B	$331.99M
7 Day Performance	-0.71%	-0.66%	-1.27%	-0.63%
1 Month Performance	7.75%	-1.07%	-0.37%	-2.00%
1 Year Performance	-78.37%	56.07%	18.30%	13.62%

Adial Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADIL Adial Pharmaceuticals	3.2417 of 5 stars	$2.78 +3.7%	$17.17 +517.5%	-76.8%	$5.75M	N/A	N/A	20	Positive News
NRSN NeuroSense Therapeutics	3.5948 of 5 stars	$0.68 -1.2%	$8.50 +1,148.2%	-70.3%	$22.79M	N/A	N/A	10	Gap Up
SKYE Skye Bioscience	2.111 of 5 stars	$0.64 -1.8%	$8.50 +1,224.0%	-83.7%	$22.56M	N/A	N/A	11
ALVR AlloVir	N/A	$4.38 -5.0%	N/A	+46.9%	$22.09M	N/A	N/A	110	High Trading Volume
JSPR Jasper Therapeutics	2.9311 of 5 stars	$0.78 -4.2%	$12.00 +1,438.5%	-78.0%	$21.84M	N/A	N/A	20	News Coverage Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. NRSN, SKYE, ALVR, JSPR, and MRKR

How does Adial Pharmaceuticals compare to NeuroSense Therapeutics?

Summary

How does Adial Pharmaceuticals compare to Skye Bioscience?

Summary

How does Adial Pharmaceuticals compare to AlloVir?

Summary

How does Adial Pharmaceuticals compare to Jasper Therapeutics?

Summary

How does Adial Pharmaceuticals compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. NRSN, SKYE, ALVR, JSPR, and MRKR

How does Adial Pharmaceuticals compare to NeuroSense Therapeutics?

Does the media refer more to ADIL or NRSN?

Is ADIL or NRSN more profitable?

Which has stronger valuation & earnings, ADIL or NRSN?

Do analysts rate ADIL or NRSN?

Do institutionals and insiders have more ownership in ADIL or NRSN?

Which has more volatility and risk, ADIL or NRSN?

Summary

How does Adial Pharmaceuticals compare to Skye Bioscience?

Which has better earnings and valuation, ADIL or SKYE?

Do institutionals & insiders have more ownership in ADIL or SKYE?

Does the media refer more to ADIL or SKYE?

Do analysts rate ADIL or SKYE?

Which has more risk & volatility, ADIL or SKYE?

Is ADIL or SKYE more profitable?

Summary

How does Adial Pharmaceuticals compare to AlloVir?

Which has more volatility & risk, ADIL or ALVR?

Is ADIL or ALVR more profitable?

Do insiders & institutionals have more ownership in ADIL or ALVR?

Which has preferable valuation and earnings, ADIL or ALVR?

Do analysts rate ADIL or ALVR?

Does the media refer more to ADIL or ALVR?

Summary

How does Adial Pharmaceuticals compare to Jasper Therapeutics?

Which has more risk and volatility, JSPR or ADIL?

Which has higher earnings & valuation, JSPR or ADIL?

Do institutionals & insiders believe in JSPR or ADIL?

Does the media prefer JSPR or ADIL?

Is JSPR or ADIL more profitable?

Do analysts recommend JSPR or ADIL?

Summary

How does Adial Pharmaceuticals compare to Marker Therapeutics?

Do analysts rate ADIL or MRKR?

Which has stronger earnings & valuation, ADIL or MRKR?

Does the media favor ADIL or MRKR?

Do insiders & institutionals believe in ADIL or MRKR?

Which has more risk and volatility, ADIL or MRKR?

Is ADIL or MRKR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools